Cardiol Therapeutics (TSE:CRDL) Stock Falls 1.7% – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) shares traded down 1.7% during trading on Wednesday. The stock traded as low as C$2.33 and last traded at C$2.37. Approximately 76,403 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 135,545 shares. The stock had previously closed at C$2.41.

Cardiol Therapeutics Stock Performance

The business has a 50-day moving average of C$2.45 and a 200 day moving average of C$1.96. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.55 and a quick ratio of 6.84. The company has a market cap of C$250.32 million, a PE ratio of -6.06 and a beta of 0.58.

Cardiol Therapeutics (TSE:CRDL) last announced its earnings results on Wednesday, August 12th. The company reported C($0.05) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.